- Conditions
- Alopecia Areata
- Interventions
- Rosnilimab, Placebo
- Biological
- Lead sponsor
- AnaptysBio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Encinitas, California • Northridge, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 938
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma
- Interventions
- Pembrolizumab/Vibostolimab, Pembrolizumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 30
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 22 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- NIS793, Bevacizumab, Modified FOLFOX6, FOLFIRI, Tislelizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri + 4 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 17
- States / cities
- Duarte, California • Fullerton, California • La Jolla, California + 12 more
- Conditions
- Breast Neoplasms
- Interventions
- pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer
- Interventions
- Pembrolizumab, Lenvatinib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 14
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 11 more
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Fluorouracil, Irinotecan, Irinotecan Hydrochloride, Leucovorin, Leucovorin Calcium, Nivolumab, Oxaliplatin, Therapeutic Conventional Surgery
- Drug · Biological · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- REGN2810, REGN2810/chemo/ipi, Chemotherapy, Placebo
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 789 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 9
- States / cities
- Rancho Mirage, California • Riverside, California • Whittier, California + 6 more
- Conditions
- Melanoma
- Interventions
- High dose bolus interleukin-2 (HD IL2)
- Drug
- Lead sponsor
- Ahmad Tarhini
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Electronic Health Record Review, Interview, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- University of Rochester NCORP Research Base
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 259
- States / cities
- Jonesboro, Arkansas • Anaheim, California • Antioch, California + 203 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Boserolimab, MK-4830, diphenhydramine, acetaminophen, MK-0482
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
- Interventions
- Combination of varlilumab and nivolumab
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more
- Conditions
- Multiple Myeloma
- Interventions
- lenalidomide, pidilizumab, pharmacological study, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Columbus, Ohio
- Conditions
- Parkinsons Disease (PD), Healthy Elderly Volunteers
- Interventions
- [¹⁸F]MK-0947
- Drug
- Lead sponsor
- XingImaging, LLC
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
- Interventions
- Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
- Device · Drug
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Pembrolizumab, Y90 radioembolization
- Drug · Device
- Lead sponsor
- Ashwin Somasundaram
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Chapel Hill, North Carolina • Seattle, Washington
- Conditions
- Melanoma
- Interventions
- Dapansutrile, Pembrolizumab
- Drug
- Lead sponsor
- April Salama, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Esophageal Neoplasms
- Interventions
- Pembrolizumab, Placebo, Cisplatin, 5-FU
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 749 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 12
- States / cities
- West Los Angeles, California • Chicago, Illinois • Westwood, Kansas + 9 more
- Conditions
- Parkinson's Disease
- Interventions
- Glycerol Phenylbutyrate
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Sarcoma
- Interventions
- Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], Nivolumab IV Soln 100 MG/10ML, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
- Drug
- Lead sponsor
- Sarcoma Oncology Research Center, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Stage IV Bladder Urothelial Carcinoma, Prostate Cancer, Urothelial Carcinoma
- Interventions
- Computed Tomography, Laboratory Biomarker Analysis, Pembrolizumab, Positron Emission Tomography, Recombinant EphB4-HSA Fusion Protein
- Procedure · Other · Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2030
- U.S. locations
- 9
- States / cities
- Duarte, California • Los Angeles, California • Newport Beach, California + 5 more
- Conditions
- Cancer, Non Small Cell Lung Cancer Metastatic, Metastatic Melanoma, Neoplasm of Lung, Melanoma
- Interventions
- APX005M, Nivolumab
- Drug
- Lead sponsor
- Apexigen America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Duarte, California • New Haven, Connecticut + 8 more
- Conditions
- Neoplasms
- Interventions
- MK-4830, Pembrolizumab, Carboplatin, Pemetrexed, Lenvatinib, Paclitaxel, Cisplatin, MK-4830A
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 9
- States / cities
- San Francisco, California • Detroit, Michigan • St Louis, Missouri + 6 more